Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q13588
UPID:
GRAP_HUMAN
Alternative names:
-
Alternative UPACC:
Q13588
Background:
The GRB2-related adapter protein plays a pivotal role in transmitting signals from receptor and cytoplasmic tyrosine kinases to the Ras signaling pathway. Its involvement is crucial for the proper functioning of the inner ear, directly impacting hearing capabilities as evidenced by research findings (PubMed:30610177).
Therapeutic significance:
Linked to Deafness, autosomal recessive, 114, a condition characterized by congenital profound sensorineural hearing loss, the GRB2-related adapter protein's genetic variants offer a promising target for therapeutic intervention. Understanding its role could pave the way for innovative treatments.